![Bristol-Myers Squibb / Pharmacology / Fixed dose combination / Organofluorides / Cyclopropanes / Emtricitabine/tenofovir/efavirenz / Tenofovir / Efavirenz / Emtricitabine / Gilead Sciences / Organic chemistry / Chemistry Bristol-Myers Squibb / Pharmacology / Fixed dose combination / Organofluorides / Cyclopropanes / Emtricitabine/tenofovir/efavirenz / Tenofovir / Efavirenz / Emtricitabine / Gilead Sciences / Organic chemistry / Chemistry](https://www.pdfsearch.io/img/52bbf0b446ceb622fcdaf399507a892f.jpg) Date: 2015-01-26 14:47:21Bristol-Myers Squibb Pharmacology Fixed dose combination Organofluorides Cyclopropanes Emtricitabine/tenofovir/efavirenz Tenofovir Efavirenz Emtricitabine Gilead Sciences Organic chemistry Chemistry | | • New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine clearance before initiating treatment with ATRIPLA. In patients at risk for renal dysfunctiAdd to Reading ListSource URL: www.accessdata.fda.govDownload Document from Source Website File Size: 1,19 MBShare Document on Facebook
|